(Total Views: 446)
Posted On: 05/26/2022 7:02:59 PM
Post# of 148984
Overall the analyst predicts Trodelvy could penetrate up to 51% of the mTNBC market...referred to by others as "fancy Chemotherapy...." as it comes with some tolerability issues much like SOC chemo drugs. Along with other issues, Neutropenia
is a big issue for Trodelvy as compared to the chemo group.
Many oncologists prioritize efficacy above safety...Trodelvy's use in later-line mTNBC could be close to "universal", but because of the less than favorable tolerances for the older population in mTNBC...analysts suggest they would assign 30% - 40% penetration for Trodelvy...in second-third line HR-positive Breast Cancer.
Initial off-label use coming out of ESMO data may be slow,... but it also suggests that with ACTIVE marketing, Gilead should be able to unlock the full market opportunity for Trodelvy as it begins to leverage/energize its marketing salesforce....(do you want to live longer)?...what a scintillating pitch!... I am waiting for our OS on mTNBC...It should choke the life out of the C-Suite at Gilead.
is a big issue for Trodelvy as compared to the chemo group.
Many oncologists prioritize efficacy above safety...Trodelvy's use in later-line mTNBC could be close to "universal", but because of the less than favorable tolerances for the older population in mTNBC...analysts suggest they would assign 30% - 40% penetration for Trodelvy...in second-third line HR-positive Breast Cancer.
Initial off-label use coming out of ESMO data may be slow,... but it also suggests that with ACTIVE marketing, Gilead should be able to unlock the full market opportunity for Trodelvy as it begins to leverage/energize its marketing salesforce....(do you want to live longer)?...what a scintillating pitch!... I am waiting for our OS on mTNBC...It should choke the life out of the C-Suite at Gilead.
(1)
(0)Scroll down for more posts ▼
